GEFTINAT 250MG GEFTINIB TABLETS IP

Get a Price/Quote

GEFTINAT 250MG GEFTINIB TABLETS IP Specification

Salt Composition
Gefitinib 250mg

Indication
Non-small cell lung cancer (NSCLC)

Dosage Form
Tablet

Feature
Oral administration, targeted therapy for EGFR mutation-positive NSCLC

Ingredients
Gefitinib

Application
Antineoplastic, EGFR inhibitor therapy

Physical Color/Texture
White to off-white tablet

Fermentation Smell
Odorless

Storage Instructions
Store below 30C, protected from moisture and light

Shelf Life
24 months

Clinical Classification
Anticancer agent, Tyrosine kinase inhibitor

Contraindications
Known hypersensitivity to gefitinib or excipients

Pack Size
1 x 30 Tablets per box

Available In
India and select international markets

Administration Route
Oral

Marketed By
Natco Pharma

Strength
250mg per tablet

Product Code
GEFTINAT 250mg

Patient Age Group
Adults

Prescription Requirement
Prescription only

Regulatory Status
Approved for medical use

GEFTINAT 250MG GEFTINIB TABLETS IP Trade Information

Packaging Details
PACK OF 30 TABLETS GEFTINAT

Main Domestic Market
West India

About GEFTINAT 250MG GEFTINIB TABLETS IP

Geftinat- Gefitinib

Specification :-

Brand name: Geftinat
Contains: Gefitinib
Strength: Geftinat 250 Mg
Packing : 1 Bottle Of Geftinat Contains 30 Tablets
Manufactured By : Natco

Note :-Geftinat Is A Prescription Drug And Should Be Used Under Proper Medical Guidance And Advice. Do Not Share The Medicine With Others, Since They May Be Suffering From A Problem That Is Not Effectively Treated By This Drug................

Targeted Anticancer Solution

GEFTINAT 250MG is specifically formulated for EGFR mutation-positive NSCLC, providing a targeted treatment option. As an oral tyrosine kinase inhibitor, it interferes with cancer cell growth and proliferation, offering advanced therapeutic benefits to eligible patients. Its use can lead to improved clinical outcomes when administered under professional guidance.

Precision and Convenience

Designed for oral administration, GEFTINAT 250MG allows patients the flexibility and convenience of home-based therapy. The once-daily format packaged in boxes of 30 tablets supports continuity in cancer care, aiding adherence to prescribed treatment regimens. This helps maximize the effectiveness of therapy with minimal disruption to daily life.

FAQs of GEFTINAT 250MG GEFTINIB TABLETS IP:

Q: How should GEFTINAT 250MG gefitinib tablets be taken?

A: GEFTINAT 250MG tablets are intended for oral administration and should be taken once daily with or without food, exactly as prescribed by your oncologist. Avoid altering the dose or frequency without consulting your healthcare provider.

Q: What is the primary indication for using GEFTINAT 250MG tablets?

A: GEFTINAT 250MG is indicated for the treatment of adult patients with non-small cell lung cancer (NSCLC) who have tested positive for EGFR mutations, as determined by a medical professional.

Q: When should therapy with GEFTINAT 250MG be considered?

A: Therapy is recommended when NSCLC has been diagnosed and evidence of EGFR mutation positivity is established. Your oncologist will determine the right time to initiate treatment based on your clinical profile.

Q: Where is GEFTINAT 250MG available and who can supply it?

A: GEFTINAT 250MG is available in India and select international markets through authorized distributors, exporters, suppliers, and traders. It is a prescription-only medication and should only be procured from licensed sources.

Q: What are the benefits of using GEFTINAT 250MG for NSCLC patients?

A: GEFTINAT 250MG provides targeted therapy for eligible patients, potentially resulting in improved control of cancer progression and fewer systemic side effects compared to traditional chemotherapy.

Q: How should this medicine be stored and what is its shelf life?

A: Store GEFTINAT 250MG tablets below 30C, protected from moisture and direct sunlight. The product is stable for up to 24 months when stored under recommended conditions.

Tell us about your requirement